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There is an unprecedented need to develop, manufacture, test and distribute safe and effective 
vaccines to fully control the COVID‐19 pandemic.  In particular,  the efforts to limit the spread of 
the virus have severely challenged opportunities global scientific collaboration and information 
exchange because scientists cannot come together in traditional meeting venues to hear the latest 
developments, share ideas, and establish new partnerships in person.   
 
The International Society for Vaccines (ISV) launched a virtual congress series 
www.ISVCongress.org as the leading platform for key COVID‐19 vaccine developers to share 
their progress and for the global vaccine community to contribute their collective expertise and  
wisdom about broader  aspects of the  global pandemic vaccine response. The aims were 
threefold: 1) to provide timely information about the processes put in place by regulatory agencies 
and NGOs for COVID-19 vaccine development, 2) to present primary data from groups 
developing vaccines, and 3) to provide a forum for discussion by experts about key challenges 
that confront the COVID-19 vaccine development process. 
 
From June to Aug, 2020, the ISV organized three monthly virtual congresses using a live video 
broadcasting platform.  Each congress commenced with an opening session with two leading 
experts presenting virology updates of SARS-CoV-2 or the global efforts by CEPI, NIH, the Bill 
& Melinda Gates Foundation and the US FDA. Then at each congress four major vaccine 
developers presented their progress; these developers came from institutions in North America, 
Europe, China, and Australia. The final session of each congress ended with a panel discussion 
focusing on a key question facing the development of COVID-19 vaccines.  The full list of 
speakers and panelists along with the titles of their talks and panel discussion topics can be found 
in Table 1.   
 
ISV members, as leaders in the global vaccine field, have played key roles in many COVID-19 
vaccine programs. Several speakers and panelists who participated in the congress series are ISV 
members or ISV Fellows, for example: David Weiner, John Shiver, Stanley Plotkin, and Stanley 
Perlman from the US, Denise Doolan from Australia, Anna-Lise Williamson from South Africa, 
Manon Cox from the US/Netherlands, Sarah Gilbert from the UK, and Xavier Saelens from 
Belgium. 
 
The timely and detailed information presented at the ISV Virtual Congresses highlighted a 
promising outlook for the field, that multiple candidate vaccines are moving through the clinical 
trial pipelines.  Added to that, well-organized clinical trial systems and clear regulatory review 
guidelines are in place.  That said, any COVID-19 vaccines will need to safeguard the integrity 
and quality of the vaccine development process, as well as demonstrate safety and efficacy before 
it can be finally licensed for general public application.  The availability of such vaccines to the 
global population will ultimately determine whether the COVID-19 pandemic can be fully 
controlled. The detailed programs of ISV virtual congresses can be found at ISV website 
www.isvcongress.org and the recordings of presentations are available at YouTube link 
https://www.youtube.com/channel/UC9_-f8tDAqOmVEZWqGeuFow 
 
The ISV congress series received unprecedented global attention from both vaccine professionals 
and the general public.  The sum total of registered participants was over 6000 and as many as 
1800 participants attended each congress in real-time. Global partners, including both public 
and private organizations, supported or sponsored the organization of ISV virtual congresses 
(www.isvcongress.org).  Dr. Nick Jackson from CEPI and Dr. Susan Barnett from the Bill & 
Melinda Gates Foundation (BMGF) kindly served as senior advisors to our congresses.   
 
In summary, the virtual Congress has further demonstrated the leadership position of the ISV as 
the only global organization for vaccine professionals.  We welcome more vaccine scientists and 
developers joining ISV (www.isv-online.org) to enable continued and increased scientific 
collaboration as we collectively strive to prevent suffering and loss of life from preventable 
diseases.  The ISV will continue organizing and supporting future virtual Congresses that have 
both a broader focus (such as on influenza and COVID-19 vaccines) and a country/regional 
focus for meetings organized by partner country-based/regional vaccine societies and groups 
which will facilitate participation due to language and time zone challenges.  While ISV 
membership is truly international, we also support local societies while simultaneously 
encouraging vaccine scientists to join ISV for increasing global interactions. 
Table 1  List of Congress Speakers and Titles of Presentations 
Date Name Institute Title of talk 
Keynote 
Presentations 
   
June 22 Kwok-Yung 
Yuen 
The University of Hong 
Kong 
Overview of COVID-19; pathogenesis 
and epidemiology 
 Nick Jackson CEPI Overview of COVID-19 Vaccine 
Development  
July 21 Larry Corey Fred Hutchinson 
Cancer Res. Center 
(COVID-19 Prevention 
Network) 
COVID Vaccine Planning:  The US 
Government Approach  
 Marion Gruber US FDA Regulatory Considerations in the 
Development and Licensure of COVID-
19 Vaccines  
Aug 25 Myron Cohen UNC-Chapel Hill mAbs for COVID-19:  Treatment and 
Prevention  
 Lynda Stuart Bill & Melinda Gates 
Foundation 
COVID-19 Vaccine:  How We Win the 
Race to Billions of Doses  
Vaccine 
Product 
Updates 
   
June 22 Kate Broderick Inovio Pharmaceuticals Advantages of a DNA-based Approach to 
the Development of a COVID-19 
Vaccine  
 Barney 
Graham 
VRC/NIAID/NIH Rapid COVID-19 Vaccine Development 
Enabled by Prototype Pathogen 
Preparedness 
 Sarah Gilbert University of Oxford 
(Partner: AstraZeneca) 
Rapid Progress with Development of 
ChAdOx1 nCoV-19 
 Tao Zhu CanSino Biological  Development of Adenovirus Vector 
Based COVID-19 Vaccine  
July 21 Greg Glenn Novavax Progress with the Full Length 
Recombinant Spike Protein Nanoparticle 
Vaccine 
 George Gao China CDC Development of Inactivated COVID-19 
Vaccines 
 Hanneke 
Schuitemaker  
J&J / Janssen The Development of an Ad26-based 
SARS-CoV-2 Vaccine 
 Kena Swanson Pfizer (Partner: 
BioNTech) 
COVID RNA Vaccine Candidate 
BNT162b1 
Aug 25 Keith Chappell The University of 
Queensland 
Molecular Clamp Stabilized 
Recombinant Protein Subunit Vaccine for 
COVID-19 
 John Shiver Sanofi Recombinant protein and mRNA Vaccine 
Candidates Against COVID-19 
 Jacqueline 
Miller 
Moderna Moderna’s Coronavirus Vaccine:  Early 
Clinical Data and the COVE Phase III 
Efficacy and Safety Study  
 Brian Ward Medicago Development of Plant-Derived SARS-
CoV-2 Virus-Like Particle (CoVLP) 
Vaccine 
Key Issue 
Panel 
Discussions 
   
June 22    
Key Issue: Challenges for COVID-19 Vaccines Development:  Are Human Challenge Studies 
Acceptable?   
 Peter 
Openshaw 
Imperial College 
London 
 
 Stanley 
Perlman 
University of Iowa  
 Stanley Plotkin VaxConsult   
July 21    
Key Issue: Challenges for COVID-19 Vaccines Development:  The Roles of Animal Models  
 Bart Haagmans Erasmus University   
 Vincent 
Munster 
RML/NIH  
 Linda Saif The Ohio State 
University  
 
Aug 25    
Key Issue: The Role of T and B Cell Responses and Vaccine Assay Standards for Determining 
Efficacy   
 Alessandro 
Sette 
La Jolla Institute of 
Immunology 
 
 Michel 
Nussenzweig 
The Rockefeller 
University 
 
 Neil Almond  The National Institute 
for Biological 
Standards and Control 
(NIBSC), UK 
 
 
 
 
